Ocugen (OCGN) CEO Musunuri Shankar Sells $500K of Stock

Musunuri Shankar, the Chief Executive Officer of Ocugen, Inc. (NasdaqCM: OCGN), sold 525,991 shares on October 9, 2026, for a total of $499,691. This sale was made at a price of $0.95 per share and was planned in advance.

Inside Musunuri Shankar's Trade

Shankar's sale of shares comes as he has been actively involved in trading the stock. Earlier, on September 9, 2026, he sold the same number of shares for $589,110 at a price of $1.12 each. His recent transaction reflects ongoing activity with the stock, which is currently trading significantly lower than previous levels.

Other Institutional Activity in Ocugen

Several institutional investors have also adjusted their positions in Ocugen recently. Blackrock Inc. increased its holdings by 19,697,932 shares, bringing its total to 27,002,933 shares worth about $21.1 million. State Street Corporation added 11,799,319 shares, resulting in 21,469,307 shares valued at approximately $16.8 million. Vanguard Capital Management LLC saw a smaller increase, adding 568,720 shares for a total of 14,372,598 shares worth about $11.2 million. Geode Capital Management also boosted its stake by 4,643,903 shares, ending with 8,871,013 shares valued at around $6.9 million.

Ocugen, Inc. Stock Down 0.3%

Ocugen's stock has been trading recently around $0.81 as of October 16, 2026, which is about 30.4% below its 50-day moving average of $1.16 and 45% below its 200-day average of $1.47. The stock is also down approximately 70.3% from its 52-week high of $2.73, although it remains slightly above its 52-week low of $0.78.

Recent Earnings

For the trailing twelve months, Ocugen reported revenue of $4.58 million, with a net margin of 0%. The company is expected to release its next earnings report on November 5, 2026.

Insider Buying and Selling at Ocugen, Inc.

In addition to Musunuri's recent sale, there have been other insider transactions. Director Prabhavathi Fernandes purchased 10,000 shares at $0.91 each on November 26, 2024, totaling $9,095. Chief Financial Officer Treerita Essalima Johnson-Greene bought 21,000 shares at $1.23 each on June 15, 2026, which amounted to $25,830.

Analysts Set New Price Targets

On September 10, 2026, HC Wainwright & Co. maintained a Buy rating on Ocugen with a price target of $9.50, slightly down from a prior target of $10.00. The consensus among analysts is a strong buy rating with a mean price target of $12.17 based on six opinions.

About Ocugen

Ocugen, Inc. is a biopharmaceutical company focused on developing innovative gene and cell therapies, biologics, and vaccines aimed at enhancing patient health. The company is headquartered in Malvern, Pennsylvania, and has around 116 employees.

Bottom Line

Investors should keep an eye on Ocugen's upcoming earnings report on November 5, 2026, to gain insights into the company's financial health. Shankar's recent sale adds to a pattern of trading activity that may reflect broader strategies as the stock continues to trade below its target prices.